Phase 2 Peripheral Neuropathy Trial, Recruiting NCT07555431 Sponsor: Carlos Brites Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT07555431
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been diagnosed with a confirmed HTLV-1 infection (a specific viral infection)
  • You are experiencing health symptoms or conditions linked to your HTLV-1 infection
  • You are able and willing to sign a written consent form agreeing to take part

Who may not be able to join:

  • You currently have an active HIV, Hepatitis C (with detectable virus), or active Hepatitis B infection
  • You currently have active tuberculosis (TB)
  • You have recently been taking steroid medications such as cortisone or prednisone (confirm with trial site for exact timeframe)
  • You have reduced kidney function, specifically a kidney filtration rate below a certain level (confirm with trial site)
  • You have an autoimmune disease (a condition where your immune system attacks your own body)
  • You use a wheelchair as your main way of getting around
  • You currently have an active cancer, except for a specific type linked to HTLV-1 called ATLL
  • You use alcohol or drugs in a way that might make it difficult to follow the trial requirements
  • You have any other health condition that the trial team believes could put your safety at risk (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Carlos Brites
Registry
ClinicalTrials.gov
Start date
7 May 2026
Est. completion
1 May 2028

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

HTLV-1 Proviral Load; Changes in Pain intensity (DN4 doleur scale); Changes in Spasticity; Changes in muscle strenght; Changes in motor score scales

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov